Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Strontium-89 Chloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : Q BioMed
Deal Size : Undisclosed
Deal Type : Agreement
Q BioMed Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada
Details : Strontium89 is an FDA-approved, non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer and is agnostic of the primary tumor.
Product Name : Metastron
Product Type : Radiolabeled Compounds
Upfront Cash : Undisclosed
October 08, 2021
Lead Product(s) : Strontium-89 Chloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Q BioMed
Deal Size : Undisclosed
Deal Type : Agreement